Valuation: AbbVie Inc.

Market Cap 458B 395B 372B 338B 636B 43,839B 645B 4,361B 1,709B 21,926B 1,718B 1,681B 73,031B P/E 2026 *
33x
P/E 2027 * 24.4x
Enterprise Value 518B 447B 421B 383B 720B 49,635B 730B 4,938B 1,935B 24,824B 1,945B 1,903B 82,687B EV / Sales 2026 *
7.66x
EV / Sales 2027 * 6.93x
Free-Float
95.71%
Yield 2026 *
2.65%
Yield 2027 * 2.78%
1 day+1.54%
1 week+6.19%
Current month+5.27%
1 month+4.26%
3 months+23.58%
6 months+17.75%
Current year+15.61%
1 week 247.68
Extreme 247.68
266.41
1 month 241.2
Extreme 241.2
267.47
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Director

62 0.0000%
6/30/26 Free

Director

134 0.0000%
5/8/26 Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.62%+6.19%+28.12%+75.92% 458B
+3.30%+4.43%+81.22%+131.68% 1,093B
+0.97%+5.18%+54.32%+63.96% 653B
+1.47%+0.33%+40.93%+44.20% 355B
+0.91%+2.19%+25.79%+41.02% 294B
+2.23%+3.42%+2.72%+13.38% 248B
+3.46%+5.92%+49.16%+69.10% 230B
+1.05%+0.13%-13.83%-52.44% 203B
+2.67%+8.97%+25.50%+94.97% 178B
+3.94%+7.83%+12.05%-23.35% 155B
Average +2.13%+1.32%+30.60%+45.84% 386.58B
Weighted average by Cap. +2.15%+1.49%+45.21%+69.83%

Financials

2026 *2027 *
Net sales 67.58B 58.37B 54.92B 49.92B 93.88B 6,476B 95.26B 644B 252B 3,239B 254B 248B 10,788B 73.52B 63.5B 59.74B 54.3B 102B 7,044B 104B 701B 275B 3,523B 276B 270B 11,735B
Net income 13.86B 11.97B 11.26B 10.24B 19.26B 1,328B 19.54B 132B 51.78B 664B 52.04B 50.91B 2,213B 18.91B 16.34B 15.37B 13.97B 26.27B 1,812B 26.66B 180B 70.66B 906B 71.01B 69.47B 3,019B
Net Debt 60.49B 52.25B 49.16B 44.68B 84.03B 5,796B 85.26B 577B 226B 2,899B 227B 222B 9,655B 51.66B 44.62B 41.98B 38.16B 71.76B 4,950B 72.82B 492B 193B 2,476B 194B 190B 8,246B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-08-19 US$263.65 +1.83% 1,063,288
26-08-18 US$258.92 +3.43% 5,010,229
26-08-17 US$250.33 +0.35% 4,648,771
26-08-14 US$249.46 -0.54% 4,195,386
26-08-13 US$250.82 +0.83% 4,370,406
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
258.92USD
Average target price
276.41USD
Spread / Average Target
+6.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock